CompletedPhase 1NCT00036790

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Wisconsin, Madison
Principal Investigator
Markus Renschler, MD, PA-C
Pharmacyclics LLC.
Intervention
doxorubicin hydrochloride(drug)
Eligibility
18-120 years · All sexes
Timeline
2002

Study locations (2)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00036790 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials